Rivaroxaban fails to decrease VTE incidence during trial period - Healio

Rivaroxaban fails to decrease VTE incidence during trial period  Healio

Treatment with rivaroxaban did not significantly decrease incidence of venous thromboembolism or death from VTE in a 180-day trial period, according to results ...



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more